-
公开(公告)号：US12180205B2
公开(公告)日：2024-12-31
申请号：US17276502
申请日：2019-09-18
Applicant: BIOGEN MA INC.
Inventor： Nathan Genung , Kevin M. Guckian , Jeffrey Vessels , Lei Zhang , Ryan Gianatassio , Edward Yin Shiang Lin , Zhili Xin
IPC: C07D417/14 , A61P25/28 , C07D417/06
Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.
-
公开(公告)号：US20230117898A1
公开(公告)日：2023-04-20
申请号：US17894461
申请日：2022-08-24
Applicant: BIOGEN MA INC.
Inventor： Nathan Genung , Kevin M. Guckian , Jeffrey Vessels , Lei Zhang , Ryan Gianatassio , Edward Yin Shiang Lin , Zhili Xin
IPC: C07D417/14 , C07D417/06 , C07D471/04
Abstract: Described herein are compounds represented by formula (I″) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y, Y2, R3 and R4 are defined herein.
-
公开(公告)号：US20220106305A1
公开(公告)日：2022-04-07
申请号：US17428323
申请日：2020-02-03
Applicant: BIOGEN MA INC.
Inventor： Nathan Genung , Kevin M. Guckian , Jeffrey Vessels , Lei Zhang , Ryan Gianatassio , Edward Yin Shiang Lin , Zhili Xin
IPC: C07D417/14 , C07D495/04 , C07D487/04 , C07D491/048 , C07D471/04
Abstract: Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, n and p are as defined herein.
-
公开(公告)号：US20220017506A1
公开(公告)日：2022-01-20
申请号：US17311232
申请日：2019-12-04
Applicant: BIOGEN MA INC.
Inventor： Nathan Genung , Kevin M. Guckian , Jeffrey Vessels , Lei Zhang , Ryan Gianatassio , Edward Yin Shiang Lin , Zhili Xin
IPC: C07D417/12 , C07D417/14
Abstract: Described herein are compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, m, n, and p are as defined herein.
-
公开(公告)号：US10166250B2
公开(公告)日：2019-01-01
申请号：US15783809
申请日：2017-10-13
Applicant: BIOGEN MA INC.
Inventor： Jermaine Thomas , Xiaogao Liu , Edward Yin-Shiang Lin , Guo Zhu Zheng , Bin Ma , Richard D. Caldwell , Kevin M. Guckian , Gnanasambandam Kumaravel , Arthur G. Taveras
IPC: C07D205/04 , A61K31/395 , A61K31/695 , C07C229/14 , C07C229/22 , C07C229/46 , C07C229/48 , C07C237/08 , C07C237/52 , C07C309/14 , C07C311/51 , C07D207/16 , C07D209/08 , C07D211/60 , C07D211/62 , C07D215/20 , C07D217/24 , C07D257/04 , C07D305/08 , C07D403/06 , C07D417/06 , C07F9/38 , C07F9/40 , A61K31/085 , A61K31/11 , A61K31/18 , A61K31/197 , A61K31/216 , A61K31/277 , A61K31/337 , A61K31/397 , A61K31/40 , A61K31/404 , A61K31/41 , A61K31/428 , A61K31/445 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/517 , A61K31/662 , A61K31/683 , A61K45/06 , C07C43/247 , C07C47/575 , C07C255/54 , C07D215/227 , C07D217/04 , C07D239/74 , C07D277/64 , C07D401/06 , C07F7/08 , A61K31/137 , A61K31/165 , A61K31/185 , A61K31/198 , A61K31/222 , A61K31/223 , A61K31/235 , A61K31/401
Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
-
Patent Agency Ranking
公开(公告)号：US20180028511A1
公开(公告)日：2018-02-01
申请号：US15644352
申请日：2017-07-07
Applicant: BIOGEN MA INC.
Inventor： Jermaine Thomas , Sha Mi , Edward Yin-Shiang Lin , Guo Zhu Zheng , Bin Ma , Richard D. Caldwell , Kevin M. Guckian , Gnanasambandam Kumaravel
IPC: A61K31/445 , A61K31/4545 , A61K31/4709 , A61K31/498 , C07K16/28 , A61K31/55 , A61K31/695 , A61K38/21 , A61K39/395 , A61K31/225 , C07D215/20 , C07D405/12 , C07D401/06 , C07D211/62 , C07D211/60 , A61K31/517 , C07D211/34
CPC classification number: A61K31/445 , A61K31/225 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/517 , A61K31/55 , A61K31/695 , A61K38/21 , A61K39/3955 , C07D211/34 , C07D211/60 , C07D211/62 , C07D215/20 , C07D401/06 , C07D405/12 , C07K16/2842
Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.
-
公开(公告)号：US20170239280A1
公开(公告)日：2017-08-24
申请号：US15397421
申请日：2017-01-03
Applicant: BIOGEN MA INC.
Inventor： Jermaine Thomas , Xiaogao Liu , Edward Yin-Shiang Lin , Guo Zhu Zheng , Bin Ma , Richard D. Caldwell , Kevin M. Guckian , Gnanasambandam Kumaravel , Arthur G. Taveras
IPC: A61K31/695 , A61K31/085 , A61K31/11 , A61K31/18 , A61K31/223 , A61K31/222 , A61K31/397 , A61K31/401 , A61K31/445 , A61K31/235 , A61K31/197 , A61K31/198 , A61K31/683 , A61K31/662 , A61K31/277 , A61K31/137 , A61K31/41 , A61K31/165 , A61K31/185 , A61K31/337 , A61K45/06
CPC classification number: A61K31/695 , A61K31/085 , A61K31/11 , A61K31/137 , A61K31/165 , A61K31/18 , A61K31/185 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/222 , A61K31/223 , A61K31/235 , A61K31/277 , A61K31/337 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/404 , A61K31/41 , A61K31/428 , A61K31/445 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/517 , A61K31/662 , A61K31/683 , A61K45/06 , C07C43/247 , C07C47/575 , C07C229/14 , C07C229/22 , C07C229/46 , C07C229/48 , C07C237/08 , C07C237/52 , C07C255/54 , C07C309/14 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07D205/04 , C07D207/16 , C07D209/08 , C07D211/60 , C07D211/62 , C07D215/20 , C07D215/227 , C07D217/04 , C07D217/24 , C07D239/74 , C07D257/04 , C07D277/64 , C07D305/08 , C07D401/06 , C07D403/06 , C07D417/06 , C07F7/081 , C07F9/3808 , C07F9/3834 , C07F9/4006
Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
-
公开(公告)号：US20170174710A1
公开(公告)日：2017-06-22
申请号：US15368454
申请日：2016-12-02
Applicant: BIOGEN MA INC.
Inventor： Kevin M. Guckian , Gnanasambandam Kumaravel , Bin Ma , Sha Mi , Hairuo Peng , Zhaohui Shao , Lihong Sun , Arthur G. Taveras , Zhili Xin , Lei Zhang
IPC: C07F7/08 , C07C229/50 , A61K31/196 , C07D215/12 , A61K31/47 , C07D401/04 , A61K31/4545 , A61K31/506 , C07D295/096 , A61K31/495 , C07D213/74 , A61K31/496 , A61K31/551 , C07D239/42 , C07D241/20 , A61K31/497 , C07D211/14 , A61K31/451 , C07D205/04 , A61K31/397 , C07D401/06 , A61K31/4709 , C07D491/107 , C07D209/52 , A61K31/403 , C07D451/02 , A61K31/439 , A61K31/695 , C07C233/60 , C07D215/38 , C07D451/14 , A61K45/06
CPC classification number: C07F7/081 , A61K31/195 , A61K31/196 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/439 , A61K31/451 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K45/06 , C07C211/38 , C07C217/58 , C07C229/46 , C07C229/50 , C07C233/60 , C07C233/61 , C07C235/66 , C07C2102/10 , C07C2102/42 , C07C2102/44 , C07C2102/50 , C07C2103/62 , C07C2601/10 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/42 , C07C2602/44 , C07C2602/46 , C07C2602/50 , C07C2603/62 , C07C2603/74 , C07D205/04 , C07D209/52 , C07D211/14 , C07D213/74 , C07D215/12 , C07D215/20 , C07D215/38 , C07D217/22 , C07D239/42 , C07D241/20 , C07D295/096 , C07D401/04 , C07D401/06 , C07D451/02 , C07D451/14 , C07D471/08 , C07D491/107 , C07F7/0805 , A61K2300/00
Abstract: Compounds of formula (I) can modulate the activity of one or more S1P receptors and/or the activity of autotaxin (ATX).
-
公开(公告)号：US09572824B2
公开(公告)日：2017-02-21
申请号：US14874600
申请日：2015-10-05
Applicant: Biogen MA Inc.
Inventor： Jermaine Thomas , Xiaogao Liu , Edward Yin-Shiang Lin , Guo Zhu Zheng , Bin Ma , Richard D. Caldwell , Kevin M. Guckian , Gnanasambandam Kumaravel , Arthur G. Taveras
IPC: A61K31/695 , A61K31/11 , A61K31/18 , A61K31/216 , A61K31/197 , A61K31/397 , A61K31/40 , A61K31/445 , A61K31/683 , A61K31/662 , A61K31/47 , A61K31/277 , A61K31/41 , A61K31/4709 , A61K31/472 , A61K31/337 , A61K31/517 , A61K31/428 , A61K31/404 , A61K45/06 , A61K31/085 , C07C229/14 , C07C229/22 , C07C229/46 , C07C229/48 , C07C237/08 , C07C237/52 , C07C309/14 , C07C311/51 , C07D205/04 , C07D207/16 , C07D209/08 , C07D211/60 , C07D211/62 , C07D215/20 , C07D217/24 , C07D257/04 , C07D305/08 , C07D403/06 , C07D417/06 , C07F9/38 , C07F9/40 , C07C43/247 , C07C47/575 , C07C255/54 , C07D215/227 , C07D217/04 , C07D239/74 , C07D277/64 , C07D401/06 , C07F7/08
CPC classification number: A61K31/695 , A61K31/085 , A61K31/11 , A61K31/137 , A61K31/165 , A61K31/18 , A61K31/185 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/222 , A61K31/223 , A61K31/235 , A61K31/277 , A61K31/337 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/404 , A61K31/41 , A61K31/428 , A61K31/445 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/517 , A61K31/662 , A61K31/683 , A61K45/06 , C07C43/247 , C07C47/575 , C07C229/14 , C07C229/22 , C07C229/46 , C07C229/48 , C07C237/08 , C07C237/52 , C07C255/54 , C07C309/14 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07D205/04 , C07D207/16 , C07D209/08 , C07D211/60 , C07D211/62 , C07D215/20 , C07D215/227 , C07D217/04 , C07D217/24 , C07D239/74 , C07D257/04 , C07D277/64 , C07D305/08 , C07D401/06 , C07D403/06 , C07D417/06 , C07F7/081 , C07F9/3808 , C07F9/3834 , C07F9/4006
Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
Abstract translation: 提供了在一种或多种S1P受体上具有激动剂活性的化合物。 化合物是肌氨酸 - 甙类似物，磷酸化后，可以作为S1P受体的激动剂。
-
公开(公告)号：US20240287076A1
公开(公告)日：2024-08-29
申请号：US18289438
申请日：2022-05-05
Applicant: BIOGEN MA INC. , C4 THERAPEUTICS, INC.
Inventor： Kevin M. Guckian , Eric Stefan , Corey Don Anderson , Jae Young Ahn , Morgan Welzel O'Shea , Jeremy L. Yap , Xinpeng Cheng , Brian T. Hopkins , Isaac Marx , Marta Nevalainen
IPC: C07D487/04 , A61K31/53
CPC classification number: C07D487/04 , A61K31/53
Abstract: This disclosure relates to compounds of Formula (A): BTK-L-DSM (A) or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches BTK to DSM, and BTK is a Btk binding moiety represented by Formula (I) or Formula (II) that is covalently attached to linker L: in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of Btk proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of Btk proteins. The present disclosure also provides methods of treating disorders responsive to modulation of Btk activity and/or degradation of Btk with at least one compound described herein.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.043 seconds)
